ArticleCancer science2018

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.

Kan Yonemori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.